Risdiplam improves motor function and milestones in infants: Lancet Jacinthlyn Sylvia3 Nov 2022 4:30 AM GMTA new study published in The Lancet Neurology suggests that over the course of a 24-month treatment with risdiplam, motor function and developmental...
Roche gets USFDA nod for spinal muscular atrophy therapy Evrysdi for babies below 2 months Ruchika Sharma31 May 2022 10:32 AM GMTOf the babies with 2 or 3 copies of the SMN2 gene (n=6), 100% were able to sit after one year of treatment with Evrysdi, 67% could stand and 50% of...
Once-Daily Risdiplam beneficial in patients with Types 2 and 3 SMA: Lancet Dr. Shravani Dali19 Jan 2022 3:30 AM GMTOnce-Daily Risdiplam is beneficial in patients with Types 2 and 3 spinal muscular atrophy (SMA), according to a recent study published in the Lancet....
FIRST: Roche launches Spinal Muscular Atrophy treatment Evrysdi in India Ruchika Sharma30 July 2021 8:00 AM GMTMumbai: Roche has announced the launch of Evrysdi (risdiplam), the first and only approved treatment in India for Spinal Muscular Atrophy (SMA)...
FDA approves first oral treatment for Spinal muscular atrophy Dr. Kamal Kant Kohli8 Aug 2020 1:30 AM GMTThe U.S. Food and Drug Administration has approved Risdiplam to treat patients two months of age and older with spinal muscular atrophy (SMA).This is...
